Assessing drug toxicity-induced tissue damage using advanced imaging technology
Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage
['FUNDING_OTHER'] · DURAMETRIX LLC · NIH-11099941
This study is testing a new way to use imaging technology to spot damage from cancer drugs early on, helping to find safer treatments that work better and have fewer side effects for patients like you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DURAMETRIX LLC (nih funded) |
| Locations | 1 site (OAK CREEK, UNITED STATES) |
| Trial ID | NIH-11099941 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new imaging-based technology that can detect tissue damage caused by drug toxicity in a minimally invasive way. By using this approach, researchers aim to identify harmful effects of anti-cancer drugs early in the drug development process. The technology provides objective and quantitative metrics to evaluate drug safety, which can help prioritize safer drug candidates. This could lead to more effective cancer treatments with fewer side effects for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals undergoing treatment for cancer who may be affected by the side effects of anti-cancer drugs.
Not a fit: Patients who are not currently receiving anti-cancer therapies or those with non-cancerous conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective cancer therapies by identifying toxic drug candidates early in their development.
How similar studies have performed: Other research has shown promise in using imaging technologies for toxicity assessment, indicating that this approach could be a significant advancement in drug safety evaluation.
Where this research is happening
OAK CREEK, UNITED STATES
- DURAMETRIX LLC — OAK CREEK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JOHNSON, STEVEN EDWARD — DURAMETRIX LLC
- Study coordinator: JOHNSON, STEVEN EDWARD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy, Cancer Drug, cancer therapy